New 'Sandwich' strategy aims to cut leukemia relapse without donor transplant risks

NCT ID NCT06507514

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a two-step treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot have a standard donor stem cell transplant. First, patients receive the drug blinatumomab to clear any remaining cancer cells, then they undergo their own stem cell transplant (autologous HSCT). The goal is to see if this 'sandwich' approach is safe and can reduce relapse rates while avoiding the high risks of donor transplants. Only 4 participants are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blinatumomab
What this could lead to: If this works, it could offer a safer consolidation option for B-ALL patients who cannot have a donor transplant, potentially reducing relapse without the high risks of donor transplants.
What could go wrong: This is a very early Phase 1 trial with only 4 participants, so results may not apply broadly. The combination approach is new and may still carry risks of relapse or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

The First Affliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.